Skip to main content

Provectus Biopharmaceuticals, Inc.

PVCT
Exchange
OTC
Industry
Pharmaceutical Preparations
SEC CIK
0000315545

No open-market purchases or sales by Provectus Biopharmaceuticals, Inc. insiders were filed in the last 90 days; 4 institutions reported holding it in 13F filings for Q2 2026, worth $8.97K in total; no superinvestor holds it.

13F holders, Q2 2026

Institutional positions in Provectus Biopharmaceuticals, Inc. as of Jun 30, 2026. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works

Institutional holders
4
−2 vs. Q1 2026
Shares held
129.8K
−72.6K (−35.9%) vs. Q1 2026
Total value
$8.97K
−$1.41K (−13.6%) vs. Q1 2026
New holders
0
0 more added
Sold out
2
0 more reduced

Compare with Q1 2026: new holders, sold out and not filed yet

Holders and value by quarter

Institutions reporting PVCT on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.

Institutional holdersQ2 2026: 4 institutions
Q1 2021: 8 institutionsQ2 2021: 7 institutionsQ3 2021: 8 institutionsQ4 2021: 7 institutionsQ1 2022: 7 institutionsQ2 2022: 7 institutionsQ3 2022: 7 institutionsQ4 2022: 7 institutionsQ1 2023: 7 institutionsQ2 2023: 7 institutionsQ3 2023: 6 institutionsQ4 2023: 7 institutionsQ1 2024: 6 institutionsQ2 2024: 7 institutionsQ3 2024: 7 institutionsQ4 2024: 6 institutionsQ1 2025: 7 institutionsQ2 2025: 7 institutionsQ3 2025: 7 institutionsQ4 2025: 5 institutionsQ1 2026: 6 institutionsQ2 2026: 4 institutions
Value heldQ2 2026: $8.97K
Q1 2021: $16.0KQ2 2021: $16.0KQ3 2021: $16.0KQ4 2021: $146.0KQ1 2022: $176.0KQ2 2022: $17.0KQ3 2022: $12.0KQ4 2022: $24.2KQ1 2023: $36.8KQ2 2023: $26.0KQ3 2023: $18.2KQ4 2023: $21.9KQ1 2024: $32.7KQ2 2024: $32.0KQ3 2024: $22.3KQ4 2024: $21.2KQ1 2025: $22.9KQ2 2025: $17.1KQ3 2025: $20.4KQ4 2025: $10.2KQ1 2026: $10.4KQ2 2026: $8.97K
Institutions holding PVCT and their total value by quarter
QuarterHoldersValue
Q2 20264$8.97K
Q1 20266$10.4K
Q4 20255$10.2K
Q3 20257$20.4K
Q2 20257$17.1K
Q1 20257$22.9K
Q4 20246$21.2K
Q3 20247$22.3K
Q2 20247$32.0K
Q1 20246$32.7K
Q4 20237$21.9K
Q3 20236$18.2K
Q2 20237$26.0K
Q1 20237$36.8K
Q4 20227$24.2K
Q3 20227$12.0K
Q2 20227$17.0K
Q1 20227$176.0K
Q4 20217$146.0K
Q3 20218$16.0K
Q2 20217$16.0K
Q1 20218$16.0K

Institutions, Q2 2026

Shares, value and share of portfolio for each institution holding Provectus Biopharmaceuticals, Inc.; share changes are against Q1 2026.

Institutions holding PVCT in Q2 2026
InstitutionSharesValue% of portfolioChange in sharesAction
Home Federal Bank of Tennessee100,000$6.90K0.00%00.0%Unchanged
Atlas Wealth LLC19,620$1.36K0.00%00.0%Unchanged
Financial Symmetry Inc10,191$7070.00%00.0%Unchanged
Huntington National Bank1$00.00%00.0%Unchanged
Wealth Preservation Advisors, LLC0$00.00%−52,600−100.0%Sold out
Academy Capital Management Inc0$00.00%−20,000−100.0%Sold out